Apeloa Pharmaceutical Co Ltd Capital Reinvestment Ratio
Apeloa Pharmaceutical Co Ltd capital reinvestment ratio. Apeloa Pharmaceutical Co Ltd (000739) has a Capital Reinvestment Ratio of 0.37x as of December 2025, meaning it reinvests 0% of its operating cash flow (CN¥446.18 Million) in capital expenditures (CN¥166.73 Million). Check how aggressively does Apeloa Pharmaceutical Co Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Apeloa Pharmaceutical Co Ltd (1998–2025)
Capital reinvestment ratio of Apeloa Pharmaceutical Co Ltd from 1998 to 2025. This chart tracks Apeloa Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 26 annual periods. Also explore Apeloa Pharmaceutical Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Apeloa Pharmaceutical Co Ltd Capital Reinvestment Ratio by Year (1998–2025)
Apeloa Pharmaceutical Co Ltd capital reinvestment ratio by year from 1998 to 2025. For the full cash flow conversion analysis, see Apeloa Pharmaceutical Co Ltd cash conversion from operations.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.31x | CN¥1.23 Billion | CN¥386.21 Million | ▼ -17.7% |
| 2024 | 0.38x | CN¥1.21 Billion | CN¥460.75 Million | ▼ -37.6% |
| 2023 | 0.61x | CN¥1.03 Billion | CN¥630.47 Million | ▲ +59.2% |
| 2022 | 0.38x | CN¥1.33 Billion | CN¥509.11 Million | ▼ -66.5% |
| 2021 | 1.15x | CN¥611.75 Million | CN¥701.92 Million | ▲ +283.4% |
| 2020 | 0.30x | CN¥1.06 Billion | CN¥317.12 Million | ▲ +1178.2% |
| 2019 | 0.02x | CN¥1.36 Billion | CN¥31.85 Million | ▼ -76.1% |
| 2018 | 0.10x | CN¥832.69 Million | CN¥81.62 Million | ▼ -87.4% |
| 2017 | 0.78x | CN¥209.80 Million | CN¥163.42 Million | ▼ -57.6% |
| 2016 | 1.84x | CN¥180.42 Million | CN¥331.35 Million | ▲ +79.2% |
| 2015 | 1.02x | CN¥441.16 Million | CN¥452.06 Million | ▲ +49.2% |
| 2014 | 0.69x | CN¥786.64 Million | CN¥540.22 Million | ▼ -74.1% |
| 2013 | 2.65x | CN¥190.45 Million | CN¥505.01 Million | ▲ +162.3% |
| 2012 | 1.01x | CN¥335.90 Million | CN¥339.59 Million | ▲ +41.4% |
| 2011 | 0.71x | CN¥404.62 Million | CN¥289.21 Million | ▼ -38.1% |
| 2010 | 1.15x | CN¥121.05 Million | CN¥139.81 Million | ▲ +156.9% |
| 2009 | 0.45x | CN¥208.30 Million | CN¥93.66 Million | ▼ -87.8% |
| 2008 | 3.69x | CN¥94.57 Million | CN¥349.04 Million | ▲ +455.7% |
| 2007 | 0.66x | CN¥174.20 Million | CN¥115.70 Million | ▲ +96.7% |
| 2006 | 0.34x | CN¥159.43 Million | CN¥53.84 Million | ▼ -75.7% |
| 2005 | 1.39x | CN¥87.40 Million | CN¥121.65 Million | ▼ -40.4% |
| 2004 | 2.34x | CN¥47.54 Million | CN¥111.07 Million | ▲ +179.4% |
| 2003 | 0.84x | CN¥105.36 Million | CN¥88.09 Million | ▼ -95.0% |
| 2002 | 16.78x | CN¥2.81 Million | CN¥47.23 Million | ▲ +3595.5% |
| 2000 | 0.45x | CN¥7.08 Million | CN¥3.22 Million | ▼ -16.8% |
| 1998 | 0.55x | CN¥30.10 Million | CN¥16.43 Million | — |